 Sio Gene Therapies Inc NASDAQ: SIOX has announced new biomarker data from Phase 12 study of AXO-AAV-GM1, an adeno-associated viral vector AAV9-based gene therapy candidate for GM1 gangliosidosis. This new data will be presented at the American Society of Gene Cell Therapy ASGCT today. 